

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name of entity	ABN/ARSN
Sigma Pharmaceuticals Limited	15 088 417 403

We (the entity) give ASX the following information.

Information about buy-back

1	Type of buy-back	On-market buy-back
2	Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendix 3D dated 18 November 2015)

Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day

	Before previous day	Previous day	
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	110,561,251	100,000
4	Total consideration paid or payable for the shares/units	\$80,489,817	\$81,720

Appendix 3E
Daily share buy-back notice

Before previous day	Previous day
---------------------	--------------

5	If buy-back is an on-market buy-back	<table border="1"> <tr> <td style="vertical-align: top;">Highest price paid: \$0.8525</td> <td style="vertical-align: top;">Lowest price paid: \$0.5600</td> </tr> </table>	Highest price paid: \$0.8525	Lowest price paid: \$0.5600	<table border="1"> <tr> <td style="vertical-align: top;">Highest price paid: \$0.8050</td> <td style="vertical-align: top;">Lowest price paid: \$0.8200</td> <td style="vertical-align: top;">Highest price allowed under rule 7.33: \$0.8290</td> </tr> </table>	Highest price paid: \$0.8050	Lowest price paid: \$0.8200	Highest price allowed under rule 7.33: \$0.8290
Highest price paid: \$0.8525	Lowest price paid: \$0.5600							
Highest price paid: \$0.8050	Lowest price paid: \$0.8200	Highest price allowed under rule 7.33: \$0.8290						

How many shares/units may still be bought back?

6	If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back	7,969,101
---	---	-----------

Compliance statement

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust’s constitution, relevant to this buy-back.
2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.



Sign here: _____ Date: 23 November 2015
 (Director/Company secretary)
 Print name: Jeff Sells

====
